CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines
Both will develop cancer vaccine candidates in selected haematological and solid tumour indications
Read More
Tag: mRNA
First UK patients receive experimental mRNA therapy for cancer in global trial
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359
Read More
Sanofi plans €400m annual investment in mRNA vaccines ‘centre of excellence’
Sanofi is currently collaborating with Translate Bio on a mRNA-based COVID-19 vaccine candidate
Read More
UK rolls out Moderna’s COVID vaccine
The vaccine is the third to be approved for use in the UK to protect against COVID-19
Read More
DNA production specialist Touchlight raises £42m
Proceeds will be used to ‘more than triple’ UK biotech’s manufacturing capabilities
Read More
ConserV Bio partners with eTheRNA on mRNA vaccine development
Collaboration will focus on vaccines for infectious diseases
Read More
Pfizer, BioNTech could supply EU with 300m doses of SARS-CoV-2 vaccine
The proposed deal covers the initial supply of 200 million doses and an option to purchase an additional 100 million, with deliveries starting by the end of 2020, if the vaccine is approved
Read More
GSK and CureVac form mRNA tech collaboration
GSK to make equity investment of £130m in CureVac as part of the deal
Read More
Merck invests in Moderna
Merck is investing $125 million in Moderna under a new deal that expands the firms’ 2016 partnership to develop messenger RNA cancer vaccines.
Read More
Lilly signs up to cancer vaccines with CureVac deal
Eli Lilly has signed up CureVac to develop cancer vaccines based on its mRNA technology, in a deal that could potentially be worth more than $2.6 billion to the German biotech.
Read More
Shire sells off mRNA platform to RaNA
Shire has sold off its messenger RNA therapy platform MRT to Cambridge, Massachusetts-based RaNA Therapeutics.
Read More
AZ ups stake in Moderna
AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
